Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Deciphera Pharmaceuticals (DCPH) stocks in Canada

Learn how to easily invest in Deciphera Pharmaceuticals stocks.

Deciphera Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Deciphera Pharmaceuticals stocks (DCPH.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $35.1 – a decrease of 3.61% over the previous week. Deciphera Pharmaceuticals employs 350 staff and has a trailing 12-month revenue of around $91.4 million.

How to buy shares in Deciphera Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DCPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Deciphera Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Deciphera Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Deciphera Pharmaceuticals's stock price has had significant negative movement.

Its last market close was $8.27, which is 84.99% down on its pre-crash value of $55.1 and 300.24% down on the lowest point reached during the March crash when the stocks fell as low as $33.1.

If you had bought $1,000 worth of Deciphera Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $558.97 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $126.61.

Deciphera Pharmaceuticals stock price (NASDAQ:DCPH)

Use our graph to track the performance of DCPH stocks over time.

Deciphera Pharmaceuticals shares at a glance

Information last updated 2022-01-18.
Latest market close$8.27
52-week range$7.63 - $52.43
50-day moving average $9.66
200-day moving average $28.66
Wall St. target price$12.22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.75

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Deciphera Pharmaceuticals price performance over time

Historical closes compared with the close of $8.27 from 2022-01-18

1 week (2022-01-12) -3.61%
1 month (2021-12-16) -9.42%
3 months (2021-10-19) -75.65%
6 months (2021-07-19) -75.19%
1 year (2021-01-19) -83.28%
2 years (2020-01-17) -88.08%
3 years (2019-01-18) 26.75
5 years (2017-01-15) N/A

Deciphera Pharmaceuticals financials

Revenue TTM $91.4 million
Gross profit TTM $-157,108,000
Return on assets TTM -30.04%
Return on equity TTM -57.78%
Profit margin 0%
Book value $6.52
Market capitalisation $483.6 million

TTM: trailing 12 months

Deciphera Pharmaceuticals share dividends

We're not expecting Deciphera Pharmaceuticals to pay a dividend over the next 12 months.

Deciphera Pharmaceuticals share price volatility

Over the last 12 months, Deciphera Pharmaceuticals's shares have ranged in value from as little as $7.63 up to $52.43. A popular way to gauge a stock's volatility is its "beta".

DCPH.US volatility(beta: 1.51)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Deciphera Pharmaceuticals's is 1.506. This would suggest that Deciphera Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Deciphera Pharmaceuticals overview

Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc.

Stocks similar to Deciphera Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site